The Virtual Assessment in Lewy Body Dementia: Pandemic and Beyond – A Series of 3 Webinars in 2021
The COVID-19 pandemic necessitated transition of care to telemedicine due to public health concerns. Those with LBD represent a particularly vulnerable population to the complications of COVID-19 given advanced age […]
Read More
What’s in a Name? It Depends on Who’s Using It
What’s Alzheimer’s disease (AD)? A person off the street will probably describe a memory problem. A healthcare professional will likely say the same. In fact, AD is what happens at […]
Read More
LBDA Partners with Medscape
Despite being a common form of dementia, there is still a tremendous need for more physician education on Lewy body dementia (LBD). To address this issue, LBDA is proud to […]
Read More
Shifting into Virtual Mode for LBD Research Meetings
In February of 2020 B.C. (before COVID-19), LBDA planned to host/attend 3 day-long meetings related to LBD research in June in Cleveland, OH. And then the pandemic hit. So, we […]
Read More
New Research Definition of Mild Cognitive Impairment with Lewy bodies (MCI-LB)
Most people with Lewy body dementia (LBD) will experience mild changes in thinking; over time, these symptoms, referred to as mild cognitive impairment (MCI), worsen and may become dementia. As […]
Read More
Alzheimer’s and Lewy bodies: When Two Pathologies Collide
DLB is one of two clinical diagnoses under the Lewy body dementia umbrella. When DLB co-occurs with Alzheimer’s disease, a clinical diagnosis is even more difficult to make as symptoms […]
Read More
LBD and Coronavirus: Prevention is the Best Medicine
With all of the news about the coronavirus and the condition “COVID-19,” here are some things that LBD families should keep in mind in the coming weeks and months. This […]
Read More
Loss of Attention May Suggest Faster Progression to Dementia in Very Early LBD
Like other dementias, a person doesn’t develop Lewy body dementia (LBD) overnight. Very mild symptoms worsen over time until medical attention is needed. Sometimes several years pass before these earliest […]
Read More
Biogen’s Aducanumab Clinical Trial Results Revealed
In a stunning reversal last October, pharma giant Biogen announced that its failed Phase 3 clinical trial of aducanemab in people with mild cognitive impairment or mild Alzheimer’s disease didn’t […]
Read More
Positive Results for the HARMONY Clinical Trial of Pimavanserin in Dementia-Related Psychosis
In December ACADIA Pharmaceuticals presented its top-line results from its Phase 3 clinical trial of pimavanserin in people who had dementia-related psychosis. The results had been eagerly awaited; ACADIA stopped […]
Read More